F. Gautier

发表

A combination of in silico and SAR studies to identify binding hot spots of Bcl-xL inhibitors.

S. Barillé-Nion, P. Juin, D. Vo, 2015, Bioorganic & medicinal chemistry.

Structure-activity relationship of selected polyphenol derivatives as inhibitors of Bax/Bcl-xL interaction.

P. Juin, D. Vo, F. Gautier, 2012, European journal of medicinal chemistry.

Synthesis of new mixed phenol/heterocyclic derivatives and studies of their activity as inhibitors of Bax/Bcl-xL interaction

S. Barillé-Nion, P. Juin, D. Vo, 2014 .

Design, synthesis and biological evaluation of new inhibitors of Bax/Bcl-xL interaction in cancer cells.

S. Barillé-Nion, P. Juin, D. Vo, 2014, Bioorganic & medicinal chemistry letters.

The oncogenic tyrosine kinase Lyn impairs the pro-apoptotic function of Bim

G. Robert, P. Auberger, J. Ricci, 2018, Oncogene.

Tight Sequestration of BH3 Proteins by BCL-xL at Subcellular Membranes Contributes to Apoptotic Resistance.

A. Letai, S. Tait, P. Juin, 2016, Cell reports.

BCL-xL antagonizes the deleterious effects of KRAS on mitochondrial scaffolding

A. Basseville, F. Gautier, C. Guette, 2022, bioRxiv.

Bcl-xL controls a switch between cell death modes during mitotic arrest

A. Letai, J. Ryan, S. Barillé-Nion, 2014, Cell Death and Disease.

Bcl-xL controls a switch between cell death modes during mitotic arrest

A. Letai, J. Ryan, S. Barillé-Nion, 2014, Cell Death and Disease.

E2F1 interacts with BCL‐xL and regulates its subcellular localization dynamics to trigger cell death

A. Gilmore, S. Barillé-Nion, P. Juin, 2018, EMBO reports.

TCTP contains a BH3-like domain, which instead of inhibiting, activates Bcl-xL

D. Andrews, Christopher M Johnson, C. Birck, 2016, Scientific Reports.

Opposite role of Bax and BCL-2 in the anti-tumoral responses of the immune system

P. Cartron, F. Vallette, Stéphane Martin, 2004, BMC Cancer.

Structure-guided design of pyridoclax derivatives based on Noxa / Mcl-1 interaction mode.

L. weiswald, S. Rault, L. Carlier, 2018, European journal of medicinal chemistry.

Bcl-xL controls a switch between cell death modes during mitotic arrest

A. Letai, J. Ryan, S. Barillé-Nion, 2014, Cell Death and Disease.

Bcl-xL controls a switch between cell death modes during mitotic arrest

A. Letai, J. Ryan, S. Barillé-Nion, 2014, Cell Death and Disease.

Altered glycosylation of α(s)β1 integrins from rat colon carcinoma cells decreases their interaction with fibronectin

J. Harb, F. Gautier, K. Méflah, 1996 .

First evidence that oligopyridines, α-helix foldamers, inhibit Mcl-1 and sensitize ovarian carcinoma cells to Bcl-xL-targeting strategies.

S. Rault, L. Ligat, F. Lopez, 2015, Journal of medicinal chemistry.

The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death.

P. Cartron, F. Vallette, P. Juin, 2006, Cancer research.

Targeting PUMA/Bcl-xL interaction by new specific compounds to unleash apoptotic process in cancer cells.

S. Barillé-Nion, P. Juin, N. Levoin, 2019, European journal of medicinal chemistry.

Synthesis and cytotoxicity studies of newly designed benzyl-hydroquinone derivatives

S. Barillé-Nion, P. Juin, N. Levoin, 2018, Medicinal Chemistry Research.

Expression of collagens type I and IV, osteonectin and transforming growth factor beta-1 (TGFbeta1) in biliary atresia and paucity of intrahepatic bile ducts during infancy.

B. le Bail, P. Bioulac-Sage, F. Gautier, 1999, Journal of hepatology.

Functional and physical interaction between Bcl‐XL and a BH3‐like domain in Beclin‐1

Nektarios Tavernarakis, Jean-Christophe Rain, Guido Kroemer, 2007, The EMBO journal.

Glutamine uptake and utilization of human mesenchymal glioblastoma in orthotopic mouse model

R. Deberardinis, F. Paris, C. Pecqueur, 2020, Cancer & Metabolism.

Efficient Mitochondrial Glutamine Targeting Prevails Over Glioblastoma Metabolic Plasticity

R. Teusan, J. Martinou, C. Pecqueur, 2017, Clinical Cancer Research.

Decoding and unlocking the BCL-2 dependency of cancer cells

Philippe Juin, Mario Campone, M. Campone, 2013, Nature Reviews Cancer.

Interactions between cancer-associated fibroblasts and tumor cells promote MCL-1 dependency in estrogen receptor-positive breast cancers

M. Amiot, M. Campone, S. Barillé-Nion, 2019, Oncogene.

BCL-XL directly modulates RAS signalling to favour cancer cell stemness

A. Letai, M. Campone, S. Barillé-Nion, 2017, Nature Communications.

Bax activation by the BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members

J. Hickman, P. Cartron, L. Oliver, 2009, The Journal of cell biology.

Bax Activation by Engagement with, Then Release from, the BH3 Binding Site of Bcl-xL

J. Hickman, P. Cartron, F. Vallette, 2010, Molecular and Cellular Biology.

Identification of an apoptotic cleavage product of BARD1 as an autoantigen: a potential factor in the antitumoral response mediated by apoptotic bodies.

I. Irminger-Finger, J. Harb, F. Gautier, 2000, Cancer research.

Production and characterisation of a monoclonal antibody specific for apoptotic bodies derived from several tumour cell lines.

J. Harb, F. Gautier, K. Méflah, 1999, Journal of immunological methods.

STING-dependent paracriny shapes apoptotic priming of breast tumors in response to anti-mitotic treatment

M. Campone, S. Barillé-Nion, F. Nguyen, 2020, Nature Communications.

STING-dependent paracriny shapes apoptotic priming of breast tumors in response to anti-mitotic treatment

M. Campone, S. Barillé-Nion, F. Nguyen, 2020, Nature Communications.

c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1

M. Campone, S. Barillé-Nion, P. Juin, 2011, Molecular Cancer.

ANT2 expression under hypoxic conditions produces opposite cell‐cycle behavior in 143B and HepG2 cancer cells

F. Gautier, A. Chevrollier, Y. Malthiéry, 2004, Molecular carcinogenesis.

The first alpha helix of Bax plays a necessary role in its ligand-induced activation by the BH3-only proteins Bid and PUMA.

Philippe Juin, P. Cartron, F. Vallette, 2004, Molecular cell.

Bcl-xL controls a switch between cell death modes during mitotic arrest

A. Letai, J. Ryan, S. Barillé-Nion, 2014, Cell Death and Disease.

ABT-737 and/or folate reverse the PDGF-induced alterations in the mitochondrial apoptotic pathway in low-grade glioma patients

P. Cartron, F. Vallette, P. Juin, 2011, Clinical Epigenetics.

BCL-XL directly modulates RAS signalling to favour cancer cell stemness

A. Letai, M. Campone, S. Barillé-Nion, 2017, Nature Communications.

Apoptosis induced by sodium butyrate treatment increases immunogenicity of a rat colon tumor cell line

J. Douillard, J. Harb, F. Gautier, 2004, Apoptosis.

Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL

J. Martinou, S. Montessuit, P. Juin, 2017, Cell Death & Disease.

Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL

J. Martinou, S. Montessuit, P. Juin, 2016, Cell Death and Disease.

Synthesis and biological studies of new piperidino-1,2,3-triazole hybrids with 3-aryl isoxazole side chains.

Appala Venkata Ramana Murthy, P. Juin, N. Levoin, 2021, Bioorganic & medicinal chemistry letters.

NOXA/MCL-1 axis determines cell-death decision between apoptosis and pyroptosis and the inflammatory secretome of breast cancer cells treated with anti-mitotics

S. Barillé-Nion, P. Juin, F. Gautier, 2023, bioRxiv.

E2F1 interacts with BCL‐xL and regulates its subcellular localization dynamics to trigger cell death

A. Gilmore, S. Barillé-Nion, P. Juin, 2018, EMBO reports.

Supplemental Information Tight Sequestration of BH 3 Proteins by BCL-xL at Subcellular Membranes Contributes to Apoptotic Resistance

A. Letai, S. Tait, P. Juin, 2022 .